Kornimate/medical-research-clean huggingface dataset:
prevalence of sarcopenia among elderly living in care facilities in klang valley, malaysia

Conditions: Sarcopenia; Sarcopenic Obesity

Summary: the primary aim of this study was to investigate the prevalence of age-related progressive decline in muscle mass and strength (sarcopenia) among malaysian elderly residing in long-term care facilities. it is a very important condition to study as it is associated with high incidence of fall, hospitalization and mortality.

over the past few decades, one condition that prominently affects the muscular system, known as sarcopenia, has captured the attention of healthcare experts and researchers. sarcopenia is a geriatric syndrome characterized by the involuntary, gradual and generalized deterioration of skeletal muscle mass and strength with advancing age. it is to be noted that while sarcopenia is predominantly a syndrome of the elderly, its development may also be observed in various conditions such as disuse, malnutrition and cachexia, all of which are not exclusive only to the elderly. as of now, there are still ongoing research on an international scale with regards to its epidemiology, risk factors, causative factors, adverse clinical complications, prevention and treatment. beginning in 1st of october, 2016, centres for disease control and prevention (cdc) has finally officialised an international classification of diseases, tenth revision, clinical modification (icd-10- cm) code for sarcopenia after its final proposal since april 2015. this establishment has enabled comprehensible clinical guidelines for diagnosis and treatment of sarcopenia, as well as separate reporting and data collection for sarcopenia in the medical community. in essence, sarcopenia appears to be one of the most important causes of functional impairment, physical disability and loss of independence in older adults and a prevalence study will help to estimate the deleterious effects of this condition on the elderly living in the care facility, who happen to be the less privileged group as compared to their counterparts dwelling in the community.

Eligibility criteria:
inclusion criteria: * currently residing in a long-term care facility * ability to walk, with or without the use of any walking aid * citizen of malaysia exclusion criteria: * inability to stand for height, weight and gait speed assessments * presence of cardiac pacemaker * presence of artificial limbs / prosthesis / metal implants * difficult or dangerous behaviours * severe cardiac, pulmonary, or musculoskeletal disorders * severe cognitive impairment or any disability that makes communication impossible * presence of terminal illness * co-morbidities associated with high risk of falls (e.g. parkinson's disease or cva) or that may directly influence affect gait speed

Keywords: muscle strength physical performance sarcopenia
clinical study of neoadjuvant therapy outcome prediction of muscle-invasive bladder cancer based on ptc drug sensitivity detection

Conditions: Muscle-Invasive Bladder Carcinoma

Summary: in this study, investigators plan to conduct the 3d in vitro culture ptc drug sensitivity testing of fresh tumor specimen which obtained by endoscopic biopsy or other methods. through assessing the consistency between the testing results and the patients' neoadjuvant treatment outcomes, they would evaluate the accuracy of ptc drug sensitivity testing and its application value in the individualized precision medicine for muscle-invasive bladder carcinoma.

this is a prospective observational study. in this study, researchers propose to enroll 40 participants above 18 years of age with muscle-invasive bladder carcinoma, who are going to receive the neoadjuvant therapy before surgery. collecting fresh tumor samples for ptc drug sensitivity testing, conducting neoadjuvant therapy for the subjects simultaneously. by combining ptc prediction results with the patients' clinical treatment process and medication feedback, researchers could estimate the accuracy of ptc drug sensitivity testing. completion of this research would provide real-world figures to support for the clinical application for ptc drug sensitivity testing, and a method is going to be established to guide the clinical treatment regimen for patients with muscle-invasive bladder carcinoma.

Eligibility criteria:
inclusion criteria: * 1 the lesion of biopsy was diagnosed as muscle-invasive bladder cancer * 2 age ≥ 18 years old, regardless of gender * 3 treatment plan of bladder removal surgery * 4 neoadjuvant therapy before surgery * 5 adequate fresh tumor tissue can be obtained by endoscopic biopsy for ptc drug sensitivity testing * 6 ecog 0-1, expected survival is more than 3 months * 7 normal or stable hepatic, renal, and hematopoietic function * 8 normal or stable blood pressure * 9 the subjects are willing to participate, sign an informed consent form, and have good compliance exclusion criteria: * 1 patients with incomplete clinical data * 2 central nervous system metastasis * 3 the presence of other malignant diseases was discovered during treatment, which is going to interfere the study * 4 researchers believe that the patient is not suitable for participation after comprehensive evaluation * 5 refuse the treatment or follow-up plans

Keywords: muscle-invasive bladder carcinoma (mibc) patient-derived tumor-like cell clusters (ptc)
prevention of preeclampsia with aspirin in recipients of donated oocytes.

Conditions: Pre-Eclampsia

Summary: the main objective of this trial is to study the occurrence of preeclampsia in recipients of donated oocytes receiving aspirin at an early stage during pregnancy and to compare the results with those obtained in patients receiving placebo.

various markers have been proposed for the early diagnosis of preeclampsia: determination of mean arterial pressure; presence of multiple risk factors of preeclampsia; biochemical, ultrasound, and angiogenic markers; uterine artery doppler, etc. these are used to determinate which patients have an increased risk of developing preeclampsia during gestation, and therefore carry out closer monitoring of pregnancy in this population. in addition, these markers can also identify patients at increased risk of developing other problems such as iugr or preterm labor. for nearly 30 years, there have been multiple studies trying to demonstrate that aspirin prevents the onset of preeclampsia with inconclusive results. however, recent studies in which aspirin was administered at an early stage (before 16 weeks of gestation) in patients at high risk of complications, have demonstrated a decrease in the incidence of this entity. thus, administration of aspirin to patients at high risk (patients classified with a high risk of complications during pregnancy, based on markers mentioned above) seems to be useful in preventing onset of preeclampsia, iugr and other complications, whenever it is administered at an early stage, as shown by several studies carried out so far. the incidence of preeclampsia, iugr and other complications of pregnancy is increased in patients undergoing treatment for ovulation induction, being much higher in recipients of donated oocytes. it appears that this increase may be explained by immunological processes. the focus lies on the interaction between hla-c fetal antigen with the maternal natural killer cells. we postulate, therefore, that the administration of aspirin in recipients of donated oocytes at an early stage of pregnancy, may also reduce the incidence of preeclampsia in this group of patients. moreover, it has been observed that patients with preeclampsia exhibit lower levels of vegf, plgf and papp-a (factors involved in placental angiogenesis) and that this is accompanied by an increase in the sflt1 (a potent pigf and vegf antagonist).

Eligibility criteria:
inclusion criteria: * patients over 18 years. * recipients of donated oocytes. * pregnant women. * single or twin gestations. * patients who accept the conditions of the study by signing the appropriate informed consent. exclusion criteria: * known allergy to acetylsalicylic acid . * personal history of peptic ulcer. * triplets. * use of prostaglandin inhibitors within 10 days prior to baseline. * personal history of chronic kidney, thyroid, liver or heart disease. * psychiatric or cognitive pathology that prevents understanding of the conditions of informed consent.

Keywords: see incidence of pre-eclampsia in acetylsalicylic acid group see incidence of pre-eclampsia in placebo group
clinical staging tools for the impacts of obesity on individuals

Conditions: Morbid Obesity

Summary: this study will assess various published staging tools to assess the health impacts of obesity on individuals. the aim is to identify benefits and drawbacks, and thus help obesity centres and gps better assess obese individuals as well as better identify who benefits most from having weight loss treatment.

this study will assess various published staging tools to assess the health impacts of obesity on individuals. the aim is to identify benefits and drawbacks, and thus help obesity centres and gps better assess obese individuals as well as better identify who benefits most from having weight loss treatment

Eligibility criteria:
inclusion criteria: * morbid obesity * at least 1 year follow-up after bariatric surgery exclusion criteria: * n/a
fear-focused self-compassion therapy for young breast cancer patients' fear of cancer recurrence

Conditions: Fear of Cancer Recurrence

Summary: few studies have tailored psychological intervention for fear of cancer recurrence (fcr) in young breast cancer patients, and the long-term efficacy of psychological intervention and its underlying mechanism are still unknown. to fill this knowledge gap, this protocol aims to evaluate the short-term and long-term effectiveness of fear-focused self-compassion therapy, as well as this therapy's psychological and physiological mechanisms in reducing severe fcr in young women with breast cancer. this study will be a randomized controlled trial recruiting 160 chinese young female breast cancer patients with severe fcr. participants will be randomized to the fear-focused self-compassion therapy group or control group (1:1). measurement will be completed at baseline (t0), immediately completing intervention (t1), after 3 months (t2), after 6 months (t3) and after 12 months (t4). primary outcomes are fcr severity; secondary outcomes are self-compassion, neurophysiological data (i.e., salivary alpha amylase and heart rate variability), attentional bias for fcr, rumination, catastrophizing thinking, and psychological symptoms. the fear-focused self-compassion therapy is based on the theories of fcr development and self-compassion, and consists of eight-week face to face group sessions.


Eligibility criteria:
inclusion criteria: * (1) are diagnosed with breast cancer (including various cancer stages and subtypes); * (2) are aged 18-45 years; * (3) can sign written informed consent; * (4) can read and write chinese; * (5) have severe fcr, with scores \> 13 on the fcri severity subscale. exclusion criteria: * (1) currently have psychiatric and psychological illness; * (2) have other types of tumor; * (3) had a previous cancer recurrence; * (4) are participating another psychological intervention at the start of the study or during their eight-week therapy.

Keywords: fear of cancer recurrence self-compassion therapy rct
a single intraarticular injection of platelet-rich plasma on pain and physical function in patients with ankle oa

Conditions: Ankle Osteoarthritis

Summary: platelet-rich plasma (prp) has been reported to be an effective treatment for knee osteoarthritis (oa). the application in ankle oa has rarely been investigated. the aim was to evaluate the efficacy and safety of a single intraarticular injection of prp for the treatment of patients with ankle oa.

methods: in a prospective study, patients with symptomatic ankle oa for at least 6 months were recruited. patients received a single injection of 3-ml of prp into symptomatic ankles. the primary outcome was the change from baseline in the visual analog scale (vas) pain score (0-10cm) at 6 months. secondary outcomes included the ankle osteoarthritis scale (aos) score, american orthopedic foot and ankle society (aofas) ankle/hindfoot score, single leg stance test (sls), use of rescue analgesics and patient satisfaction. adverse events were recorded during the study. patients were followed at 1, 3 and 6 months postinjection .

Eligibility criteria:
inclusion criteria: * age of at least twenty years * ankle pain lasted for at least 6 months, despite conservative treatment or inability to tolerate the side effects of medications * ankle radiographs taken within 6 months (reviewed by the senior author) were equivalent to grade 1-4 osteoarthritis by the kellgren lawrence grading system * average ankle pain of \> 3cm on a 10-cm visual analog scale (vas) * radiological evidence of bilateral ankle osteoarthritis was accepted if vas pain in the contralateral ankle was \< 3 cm * normal activity level, not bedridden or confined to a wheelchair, able to walk 30 meters without the aid of a walker, crutches or cane * no use of physical therapy or changes in shoes or orthotic devices during the study exclusion criteria: * pregnancy or lactation in women * lower leg trauma in a location other than within the ankle * previous surgery involving the spine, hip or knee * the presence of an active infection of the ankle * surgery involving the affected ankle within the previous 12 months * intraarticular steroid or hyaluronate injection in the ankle within the previous 6 months * treatment with anticoagulants or immunosuppressives * history of rheumatoid arthritis, gout, or other inflammatory arthropathy * the presence of visual or vestibular impairments * poor health status (such as a neoplasm, diabetes mellitus, or paresis) that would interfere with the assessments

Keywords: ankle joint osteoarthritis platelet rich plasma
covid19 neurological manifestation

Conditions: SARS-CoV 2; Neurologic Manifestations

Summary: this study is a prospective observational cohort study to document the prevalence and types of neurological manifestations among hospitalized patients with confirmed or suspected novel coronavirus infection (covid-19).

this study is a prospective observational cohort study to document the prevalence and types of neurological manifestations among hospitalized patients with confirmed or suspected novel coronavirus infection (covid-19). severe acute respiratory syndrome 2 (sars-cov-2), the virus that causes covid-19, shares significant structural and biological similarities with sars-cov, which is known to be neuroinvasive particularly with brainstem involvement. there are emerging reports of neurological symptoms associated with covid-19 infections, including seizures, coma, encephalitis, guillan-barre syndrome, and cerebrovascular events including ischemic stroke, ich, and cerebral venous sinus thromboses. however, the exact prevalence of these conditions and their impact on patient disease severity and outcomes is unknown. as the incidence and severity of covid-19 infection continue to rapidly rise globally, it is imperative to capture prospective data to accurately document prevalence, severity and clinical characterization of neurological components of covid 19, the influence of treatment regimens of neurological complications, and role of these confounders on patient and organizational outcomes.

Eligibility criteria:
inclusion criteria: * patients greater than or equal to 18 years old * admitted with suspected or confirmed covid19 infection * patient exhibiting acute neurological symptoms exclusion criteria: * patients under the age of 18 years old * pre-existing, baseline severe neurologic dysfunction including baseline coma/vegetative state, baseline quadriparesis, baseline refractory seizure disorder with frequent breakthrough seizures despite anticonvulsant use
classroom-level intervention to promote peers' acceptance of children with attention deficit hyperactivity disorder (adhd)

Conditions: Attention Deficit Hyperactivity Disorder

Summary: children with attention-deficit/hyperactivity disorder (adhd) comprise about 5-10% of the elementary school-age population. one place where children with adhd have great difficulty is in being accepted by peers and in making friends. it has unfortunately been very difficult for the field to find good treatments for peer relationship problems for this population. even when children with adhd do improve their behavior, it is common that peers do not seem to like the child with adhd any better. this may happen because children often have negative reputations with their classmates that are hard to change. that is, once a class of children get the impression that one child is disliked or the social outcast, even if that child's adhd symptoms get better, the peer group may not notice any of these improvements. it is hypothesized that the elementary school teacher may be able to help peers notice positive behavior changes in children with adhd when they do occur. this clinical trial will design and pilot-test an intervention that would train teachers in classroom practices to reduce the peer rejection of students with adhd. the pilot test will be conducted in a summer program created to be similar to a regular school classroom in structure. if the treatment seems to succeed in the summer program, then it will be tried in regular classrooms in a future study.


Eligibility criteria:
inclusion criteria: * children ages 6-8 * primary diagnosis of adhd exclusion criteria: * pervasive developmental disorder * verbal iq below 75

Keywords: attention deficit hyperactivity disorder (adhd)
safety study of use of hyaluronic acid gel to prevent intrauterine adhesions in hysteroscopic surgery

Conditions: Tissue Adhesions

Summary: operations in the uterus are currently possible using a hysteroscope. one serious though rare complication of such procedures is the development of intra-uterine adhesions. there currently are no methods to prevent this. the aim of this study is to evaluate the safety of using hyaluronic gel after hysteroscopic surgery.

operations in the uterus are currently possible using a hysteroscopic approach. intrauterine procedures include; polypectomy, myomectomy, removal of lost iud,removal of a septum and more. one serious though rare complication of operative hysteroscopy is the development of intra-uterine adhesions. such adhesions, also known as asherman's syndrome, can cause serious consequences such as infertility and miscarriage. the hypothesis is that the removal of the endometrium and the exposure of ra uterine wall to each other can cause attachment and adhesions. the treatment is to mechanically break the adhesion. recurrence is however common. there currently are no methods to prevent adhesions following curettage or hysteroscopy. the aim of this study is to evaluate the safety of using hyaluronic gel after hysteroscopic surgery. at a later research, the efficacy of barrier gel will be measures.

Eligibility criteria:
inclusion criteria: * age 18 year old and over * need of hysteroscopic surgery exclusion criteria: * preoperative fever or infection * malignancy * previous pid * contraindications for anesthesia * pregnancy * under 18 year old * not able to read and/or understand informed consent * taking any medicine other than oral contraceptives

Keywords: hysteroscopy postoperative complications adhesions hyaluronic gel prevention
correlation between endothelial function and trans radial-procedural events

Conditions: Injury; Blood Vessel, Wrist, Radial Artery

Summary: the aim of this study is to investigate the relation between the previous presence of endothelial dysfunction and the development of radial artery vasospasm during the trans-radial coronary evaluation.

all patient will undergo pre procedural endopat assessment for endothelial dysfunction

Eligibility criteria:
inclusion criteria: patients without angiographic proof of coronary disease, with scheduled elective coronary angiographic evaluation by radial approach. exclusion criteria: impossibility to perform radial approach; abnormal barbeau test result (type c and d); previous important trauma of the upper limbs; presence of fistule for renal dialysis; lymphedema; acute myocardial infarction, severe valvular heart disease; patients with nyha class iii and iv heart failure; malignancy; active myocarditis; hiv infection or immunodeficiency state; chronic viral infection; acute systemic infection requiring antibiotics; systemic inflammatory disease; raynaud's syndrome; refusal to sign the informed consent form. all participants must give a written informed consent
preconditioning with sevoflurane and propofol in patients undergoing minimally invasive mitral valve surgery

Conditions: Myocardial Ischemia

Summary: the main aim of this study is to compare markers of cardiac injury (troponin i), inflammatory response and platelets function during minimally invasive mitral valve repair or replacement (mimv) via right mini-thoracotomy in two standard anaesthetic regimes (sevo \\propofol)

the main aim of this study is to compare markers of cardiac injury (troponin i), inflammatory response and platelets function during minimally invasive mitral valve repair or replacement (mimv) via right mini-thoracotomy in two standard anaesthetic regimes: * volatile conditioning (sevoflurane) used during induction (preconditioning) and during the operation as maintenance (perconditioning) and no propofol. * propofol induction and maintenance (tiva) and no volatile anaesthetics. outlet/residual blood samples coming from routine check will be collected at different time points. study will be powered on troponin i (primary statistical outcome). original secondary outcome will be considered: platelets activation, left ventricle function, clinical figures (length of stay, inotrops requirements, ventilation times and other relevant).

Eligibility criteria:
inclusion criteria: 1. age ≥18 2. patients undergoing elective (or urgent) first-time minimal invasive mitral valve surgery. exclusion criteria: 1. cardiogenic shock or cardiac arrest, emergent cabg 2. renal failure (with a gfr \< 30 ml/min/1.73m2), 3. glibenclamide or nicorandil (as these medications may interfere with vc) 4. pregnancy 5. known intolerance/allergy to sevoflurane or propofol